PBH

+ Watchlist + Portfolio

Prestige Consumer Healthcare Inc.

Regulated industry Physical products Consumer brandTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $44.77
52-Week Range: $42.62 – $71.07
Market Cap: $2.14B
P/E (TTM): 12.68
EPS (TTM): 3.57
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.12
PEG Ratio: 1.43
Return on Equity: 9.12%
Return on Assets: 4.58%
Gross Margin: 54.77%
Operating Margin: 20.83%
Profit Margin: 15.57%
Current Ratio: 3.23
Debt/Equity: 1.08
Total Debt: $2.07B
Free Cash Flow: $147.89M
Revenue Growth: 6.50%
Earnings Growth: -35.80%
Enterprise Value: $4.12B

PBH Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$1.13B	$1.13B	$1.14B	$1.09B
Cost of Revenue	$502.43M	$500.91M	$503.30M	$493.13M
Gross Profit	$625.29M	$624.45M	$634.46M	$595.58M
Selling, General & Admin	$252.41M	$259.47M	$263.93M	$265.23M
Operating Expenses	$277.49M	$282.02M	$285.22M	$286.17M
Operating Income	$347.80M	$342.43M	$349.24M	$309.41M
EBITDA	$7.87M	$373.86M	$361.99M	$331.11M
Pretax Income	-$93.92M	$276.02M	$284.19M	$257.50M
Income Tax	-$11.61M	$66.69M	$69.58M	$67.19M
Net Income	-$82.31M	$209.34M	$214.60M	$190.30M
Diluted EPS	-1.65	4.17	4.29	3.91
Diluted Shares	49.89M	50.18M	50.08M	48.72M

PBH Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$58.49M	$46.47M	$97.88M	$63.87M
Receivables	$167.02M	$176.78M	$194.29M	$191.92M
Inventory	$162.12M	$138.72M	$147.71M	$159.13M
Current Assets	$391.74M	$375.04M	$448.33M	$431.48M
Total Assets	$3.35B	$3.32B	$3.40B	$3.49B
Current Liabilities	$160.72M	$117.05M	$106.62M	$120.92M
Long-Term Debt	$1.35B	$1.13B	$992.36M	$993.95M
Total Debt	$1.37B	$1.14B	$1.04B	$1.05B
Total Liabilities	$1.91B	$1.66B	$1.57B	$1.61B
Retained Earnings	$1.13B	$1.34B	$1.56B	$1.75B
Shareholders' Equity	$1.45B	$1.66B	$1.83B	$1.89B
Working Capital	$231.03M	$258.00M	$341.70M	$310.56M
Net Debt	$1.29B	$1.08B	$894.47M	$933.07M

PBH Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	$229.72M	$248.93M	$251.51M	$257.63M
Capital Expenditure	-$7.78M	-$9.55M	-$8.22M	-$11.18M
Free Cash Flow	$221.93M	$239.38M	$243.29M	$246.45M
Depreciation & Amortisation	$32.63M	$30.68M	$30.17M	$31.27M
Stock-Based Compensation	$12.40M	$14.01M	$11.16M	$10.84M
Investing Cash Flow	-$11.58M	-$20.11M	-$17.45M	-$136.84M
Financing Cash Flow	-$185.85M	-$241.01M	-$182.07M	-$156.06M
Share Repurchases	-$50.00M	-$25.00M	-$51.51M	-$156.28M
Net Change in Cash	$32.29M	-$12.20M	$51.99M	-$35.28M

PBH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$296.52M	$249.53M	$274.11M	$283.44M	$281.62M	$265.71M
Cost of Revenue	$126.51M	$109.20M	$122.53M	$126.08M	$135.32M	$129.52M
Gross Profit	$170.01M	$140.33M	$151.58M	$157.37M	$146.30M	$136.19M
Selling, General & Admin	$64.05M	$63.39M	$66.74M	$69.73M	$65.37M	$77.97M
Operating Expenses	$69.12M	$68.58M	$71.91M	$74.88M	$70.81M	$83.67M
Operating Income	$100.89M	$71.76M	$79.67M	$82.49M	$75.49M	$52.52M
EBITDA	$91.97M	$79.65M	$86.83M	$80.08M	$84.55M	$61.24M
Pretax Income	$73.96M	$61.78M	$69.13M	$61.81M	$64.77M	$38.54M
Income Tax	$23.83M	$14.31M	$26.92M	$15.12M	$10.84M	$9.36M
Net Income	$50.13M	$47.47M	$42.21M	$46.70M	$53.93M	$29.18M
Diluted EPS	1.00	0.95	0.86	0.97	1.13	0.61
Diluted Shares	50.06M	49.83M	49.26M	48.09M	47.69M	47.60M

PBH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$97.88M	$139.50M	$119.11M	$62.37M	$63.87M	$89.13M
Receivables	$194.29M	$168.41M	$199.00M	$190.46M	$191.92M	$187.35M
Inventory	$147.71M	$153.13M	$159.00M	$163.59M	$159.13M	$190.22M
Current Assets	$448.33M	$480.52M	$497.41M	$433.43M	$431.48M	$496.81M
Total Assets	$3.40B	$3.43B	$3.44B	$3.49B	$3.49B	$4.57B
Current Liabilities	$106.62M	$109.67M	$134.60M	$139.56M	$120.92M	$153.81M
Long-Term Debt	$992.36M	$992.75M	$993.15M	$1.03B	$993.95M	$2.01B
Total Debt	$1.04B	$1.04B	$1.04B	$1.08B	$1.05B	$2.07B
Total Liabilities	$1.57B	$1.58B	$1.62B	$1.67B	$1.61B	$2.65B
Retained Earnings	$1.56B	$1.60B	$1.65B	$1.69B	$1.75B	$1.78B
Shareholders' Equity	$1.83B	$1.86B	$1.82B	$1.83B	$1.89B	$1.92B
Working Capital	$341.70M	$370.85M	$362.81M	$293.87M	$310.56M	$343.01M
Net Debt	$894.47M	$853.25M	$874.04M	$971.17M	$933.07M	$1.93B

PBH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$61.85M	$79.01M	$57.49M	$78.29M	$42.84M	$70.79M
Capital Expenditure	-$3.48M	-$838.00K	-$2.10M	-$3.03M	-$5.21M	-$3.70M
Free Cash Flow	$58.37M	$78.17M	$55.38M	$75.26M	$37.63M	$67.08M
Depreciation & Amortisation	$7.25M	$7.67M	$7.66M	$7.59M	$8.35M	$8.75M
Stock-Based Compensation	$2.73M	$3.68M	$1.77M	$2.74M	$2.65M	$3.99M
Investing Cash Flow	-$3.48M	-$1.94M	-$2.93M	-$128.56M	-$3.41M	-$1.06B
Financing Cash Flow	-$11.49M	-$36.28M	-$74.95M	-$6.73M	-$38.10M	$1.02B
Share Repurchases	-$11.31M	-$34.77M	-$75.00M	-$45.82M	-$690.00K	$0.00
Net Change in Cash	$46.88M	$40.79M	-$20.39M	-$57.01M	$1.33M	$25.50M

Market Snapshot

About

Prestige Consumer Healthcare Inc. develops, manufactures, and markets over-the-counter healthcare and household cleaning products. The company owns brands including Monistat, Clear Eyes, Chloraseptic, Dramamine, Luden throat drops, Compound W, and Debrox, distributed primarily in North America and Australia.